ELEM Biotech

A new paper signed ‘ELEM biotech’ is out now, and has been published in #Nature npj Digital Medicine! Why is this paper a big step forward for proarrhythmic #Risk management? Because it demonstrates how introducing in silico modeling to #DrugDevelopment can improve preclinical #reliability, supporting decision making with relevant #insights such as:? ?? Sex-specific responses? ?? Complex cardiac responses? ?? Accurate predictions of drug-induced QT prolongation? Read our new paper and discover how this approach enables #rapid, Multi-dose drug testing on standard hardware, addressing critical industry challenges around trial design, assay variability, and cost-effective #safety evaluations: ?? https://lnkd.in/dMN7gUAM To learn more about the potential of integrating #VirtualHumans in clinical studies, contact us at [email protected]! Congratulations to Paula Domínguez Gómez Alberto Zingaro Caterina Balzotti Laura Baldó Canut Borje Darpo Christopher Morton Mariano Vazquez Jazmin Aguado-Sierra for your exceptional work!

This week, elEconomista published an article following an interview with our CEO Christopher Morton, highlighting how at ELEM we develop Virtual Human Twins that support the #healthcare industry saving time and money by predicting #human responses to #treatments. What are the benefits of integrating #VirtualHumans in the therapy development process? ?? Identify #risks early: Virtual Human Twins assess human risk indicators during drug development, enabling #decisions to halt ineffective treatments—saving over a billion euros before clinical trials. ?? #Diverse patient modeling: Virtual populations simulate hormonal changes, age, and comorbidities, enabling safe testing for groups like pregnant and pediatric patients—currently impossible in real-world trials. Read the article here for more insights, or contact us at [email protected] to understand how our Virtual Human #technology can provide you with new #evidence for #safer and better therapeutics! ??https://lnkd.in/d9C7a79V

International Women’s Day is an opportunity to reflect on the progress needed in the fight for women’s rights and inclusion. In healthcare, we continue to face challenges, particularly with the #UnderRepresentation of #women in clinical trials. Fortunately, a growing push is underway to address this issue. In the FDA’s “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies” (June 2024), the importance of enrolling underrepresented groups, including women, is emphasized. The guidance states: “Sponsors should consider whether certain demographic groups (e.g., #females, older patients, pediatric patients, a particular race or ethnic group) may have a different response to the medical product—either differential #effectiveness or #safety. In some cases, it may be necessary to increase the proportional enrollment of a certain population in the clinical study to evaluate outcomes of interest or other clinically relevant factors in that group.” By enabling sponsors to account for key #factors like metabolite imbalances and co-morbidities, ELEM helps ensure balanced female/male cohorts, which strengthens the evidence supporting regulatory filings and drives more inclusive, effective #healthcare solutions. ?? Learn more about FDA guidance: https://lnkd.in/gNczUwNA Contact us for more information on how ELEM #SexSpecific evidence can increase significance of clinical trials results, at [email protected] #WomensHealth #SexDifferences #WomensHealthInvestment #HealthInnovation

How to prevent trial failures? This interesting post on 10 examples of #clinicaltrial failures from 2024 leads to reflections on improvements. Take Cassava Sciences' simufilam, a drug for mild to moderate Alzheimer’s disease—it failed to meet its primary endpoints in Phase 3, showing no significant cognitive or functional improvement compared to #placebo. ?? What could have been done differently to protect Cassanova Sciences, reducing financial and time costs? The #failure could have been predicted before reaching an expensive and lengthy Phase 3 trial by testing on Virtual Human #simulations. By modeling diverse patient populations, ELEM’s technology might have identified early on whether any subgroups could benefit from the drug. Our Virtual Humans provide a powerful tool for #safer clinical trials, simulating sex-specific electrophysiological variability to improve early-stage drug safety assessment. Read this recent ELEM paper to learn how our technology can support better decision-making in drug development: ?? https://lnkd.in/dzF3wvge

As our CEO Christopher Morton mentions in this post, ELEM #VirtualHumans enable #healthcare companies to execute bigger, faster and safer #ClinicalTrials. Visit us in Hall 8, stand 8.0C1 and learn how our cloud-deployed platform V.HEART can help you generate the #evidence that will complement your Investigation product dossier!

ELEM is taking part to #MWC! You can find our CTO Mariano Vazquez in Hall 8, Stand 8.0C1! visit us and learn about our #VirtualHuman Technology for Biomedical industries. MWC Barcelona 4YFN #MobileWorldCongress #4YFN #MWCBarcelona #4YFN25

Abnormal thickening of the #heart is a symptom that could be an alarm for many conditions.? Participating in Hypertrophic Cardiomyopathy (#HCM) Awareness Day, we highlight the importance of understanding #complex #cardiac conditions. HCM has a #genetic component and varying risk levels. ELEM’s physics-based & Data-driven in human models deliver #PatientSpecific insights, which are crucial for managing this and other complex cardiac conditions. With ELEM #VirtualHumans, #therapeutic efficiency can be optimized for #tailored groups of patients based on alternative treatment strategies. By integrating specific physiological and anatomical markers — such as heart morphology or its electrical, mechanical and hemodynamics function — our technology enables more #precise, #safer and #evidence-based #decisions. Contact us at [email protected] for further information about our Virtual Humans #HCMAwarenessDay #HeartMonth

Yesterday, ELEM attended a roundtable on #Women's Health, focusing on #Cardiovascular Health. How did Women's Health Access Matters address the urgent need to accelerate research and investment in this underrepresented market? As highlighted, more than 45% of women over 20 have some form of cardiovascular disease and yet, just 4% of NIH research funding is dedicated to women’s heart disease. What is preventing progress in cardiovascular innovation for women? ?? Lack of #awareness: Cardiovascular disease is the Number 1 killer of women, yet investors, healthcare stakeholders and women themselves are unaware of the risks and need for #sexbased research. ??Outdated research: although women represent 51% of the population, they are underrepresented in trials, and research guidelines often do not include gender-balanced study groups ?? Reproductive health limits - Women's health has long been limited to #reproductive health, ignoring the broader impact of life stages such as #menstruation, #pregnancy, #menopause, and conditions such as #lupus or #endometriosis on cardiovascular risk. Today women's health has to be addressed differently. Integrating ELEM #VirtualHumans in the therapy development process, opens the door to sex-specific #Data and enables new, #representative trials for earlier #detection and better women healthcare. Contact us to learn more about ELEM #solution to this problem, at [email protected] #WomensHealth #WomensHeartHealth #HeartHealth #InvestmentinHealth #HealthInnovation #WomensHealthResearch #WHAMNow

This month our CTO Mariano Vazquez was interviewed by #ARTE France, who visited ELEM to explain what are our #VirtualHumans and how they are making #therapies development #safer and #better, by predicting the outcome of patients responses.?? Watch the entire video that was published on #Swiss, #France and #German tv, by following this link:? ?? https://lnkd.in/d3R4rzsD Contact us to learn more about the potential of integrating ELEM #VirtualHumans in your #clinical studies, at [email protected]

This week ELEM participated in the report presentation of Biocat, BioRegion of Catalonia, Europe hubspot for #healthcare new technologies. Our CEO Christopher Morton joined a panel discussion on the challenges and opportunities shaping the future of Global Life Sciences. In addition, other #challenges discussed during the day regarded: ??Healthcare transformations across Europe – such as France 2030 program of investments in healthcare innovation, Denmark’s national Agency for Digital Health or UK’s investments in public healthcare digitalization ?? Evolving medication markets – from #womenhealthcare to anti-obesity drugs or longevity treatments? ??EU investments & latest #regulations shaping healthcare innovation - such as Data protection regulations (GDPR), Health #Data sharing (EHDS) or EU AI Act Now is the time to face these challenges with the support of ELM #VirtualHuman technology for?#safe and optimized #drugdevelopment, accessing new unparalleled scientific #evidence that accounts for #sexspecific characteristics and population #variability. Concluding with what shared by Jorge Juan Fernández García… “There is a time to let things happen and a time to make things happen” Let’s make it happen. Contact us at [email protected]!